Camber Capital Management’s Crescent Biopharma CBIO Stock Holding History

Camber Capital Management’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-22,000	Closed	-$8.27M	–	40
2020 Q4	$8.27M	Sell	22,000 -3,000	-12%	-$1.05M	0.29%	32
2020 Q3	$7.67M	Sell	25,000 -5,000	-17%	-$1.91M	0.4%	31
2020 Q2	$11.3M	Sell	30,000 -5,000	-14%	-$1.42M	0.65%	27
2020 Q1	$7.98M	Hold	35,000	–	–	0.48%	26
2019 Q4	$18.5M	Hold	35,000	–	–	0.94%	26
2019 Q3	$15.1M	Buy	+35,000	New	+$22.5M	0.79%	30

Other funds holding CBIO

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Camber Capital Management's CBIO Position: Q1 2021 in Review

Camber Capital Management sold out of Crescent Biopharma (CBIO) in Q1 2021, closing a stake of 22,000 shares — an estimated $8.27M sold.

Camber Capital Management first reported a position in CBIO in Q3 2019 and held it in 6 quarters. The position peaked at $18.5M in Q4 2019. 78 funds tracked by Wall St. Rank hold CBIO as of Q1 2021.

Camber Capital Management reported no remaining Crescent Biopharma position as of Q1 2021 after selling out during the quarter.
Camber Capital Management sold 22,000 Crescent Biopharma shares in Q1 2021, an estimated $8.27M.
Camber Capital Management first reported a position in Crescent Biopharma in Q3 2019 and held it in 6 quarters.
Camber Capital Management's Crescent Biopharma position peaked at $18.5M in Q4 2019.
78 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2021.

Based on Camber Capital Management's 13F filing for Q1 2021, filed 17 May 2021.